MyChesCo on MSN

Virion Therapeutics reports Phase 1b data for HBV immunotherapy VRON-0200

PHILADELPHIA, PA — Virion Therapeutics LLC reported data showing its experimental hepatitis B immunotherapy VRON-0200 ...
Seeking Alpha

Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic ...

PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean ...
ksn.com

Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B ...

Providence, RI, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research ...
Seeking Alpha

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing ...

Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (OCEA) (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research ...
KOIN 6

Virion Therapeutics Reports First-Ever Clinical Responses with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at AASLD's The Liver Meeting®

Ongoing safety (N=25) and immunogenicity (n=22), and first report of anti-HBV activity, presented in chronically HBV-infected patients following a single, prime-only intramuscular injection of ...
News Medical

Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

A new study reveals how C210, a curcumin derivative, selectively reactivates Epstein–Barr virus to kill cancer cells without infectious risks, paving the way for safer, targeted cancer therapies.